Not targeting anyone, @Led, in my post. Just like to draw people’s attention to the question of the company specifics, and whether they may be strong enough to handle the macro environment.
What one should remember is that once the minutes for the heart meeting is out in 3 weeks’ time, the company will announce its detailed feedback - this much was said in its latest announcement. To me, that says the next stage is firmly back in the company’s court. It will be able to take to any third parties any confirmatory trial design (number of sites, enrolment etc) which it most clearly discussed with the FDA already and funding needs. These are things that are the “controllables” and very important to winning goals and not just setting them. It is important for putting product on shelves.
MSB Price at posting:
$1.86 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)